Scientific and Clinical Initiatives

Home Research Scientific and Clinical Initiatives

Dedicated to improving patient outcomes, the Pancreatic Cancer Action Network (PanCAN) pioneers revolutionary clinical initiatives and supports leading-edge research.

To date, PanCAN's cumulative research investment is projected to be approximately $126 million, including our research grants program and clinical initiatives.

Research Grants Program

Through a competitive grants process, we fund innovative research. Since 2003, we have awarded 199 grants to 187 scientists at 71 institutions. Meet our newest recipients and read the latest stories about our grantees and their work.

Clinical Initiatives

Precision Promise is PanCAN’s groundbreaking platform designed to accelerate new treatment options for pancreatic cancer patients. This approach includes basic and translational research funding, key opinion leader and industry partnerships, early-stage clinical development and ultimately evaluating therapies for potential FDA approval through our adaptive clinical trial. In addition, we will be investigating supportive care measures, and we will analyze extensive patient data to better understand what makes every patient’s tumor unique. Precision Promise is designed to serve as a catalyst to accelerate pancreatic cancer drug development, de-risk industry participation, increase clinical trial enrollment and transform the way clinical research is done for pancreatic cancer patients.

Learn More

Precision Promise-related News

View More News →

Studies from PanCAN and others have suggested that patients treated with matched therapies selected through molecular profiling have better outcomes. We support the National Comprehensive Cancer Network guidelines recommendation that all pancreatic cancer patients undergo tumor tissue molecular profiling and genetic testing of a blood or saliva sample. PanCAN offers information and resources related to precision medicine, including the Know Your Tumor precision medicine service, for healthcare professionals and their patients.

PanCAN, along with Perthera Inc. and other partners, published findings in Lancet Oncology that analyzed the first 1,080 patients to receive molecular profiling reports through Know Your Tumor. The data showed that one out of every four patients had an “actionable” alteration that can inform treatment decisions. And, patients who were able to go on a therapy that matched their tumor biology lived an average of one year longer compared to patients who weren’t.

Learn More

Know Your Tumor-related News

View More News →

PanCAN's Patient Registry is a global online database created to look for patterns in treatments, side effect management and diagnostics that will lead to improved treatment options and outcomes for patients.

De-identified patient health data provides researchers with crucial details that will help them make discoveries. PanCAN encourages patients to share their health data with trusted parties such as the Patient Registry.

Are you a researcher or healthcare professional with questions about the patient experience? Partner with PanCAN to answer research questions you may have.

According to our registry data, nausea is the best managed symptom or side effect pancreatic cancer patients experience. But fatigue, pain and depression are generally unmanaged. These results, which were shared at the 2019 Gastrointestinal Cancers Symposium, underscore the need for the healthcare community to address and manage these symptoms to improve patient lives.

Learn More

Patient Registry-related News

View More News →

Pancreatic cancer patients who participate in clinical research have better outcomes. Clinical trials can advance research and improve treatment options. PanCAN offers clinical trials information personalized for you and your patients, and our Clinical Trial Finder provides free access to the most comprehensive and up-to-date database of pancreatic cancer clinical trials in the United States.

At the 2019 Gastrointestinal Cancers Symposium, PanCAN contributed to a poster evaluating how many patients search for clinical trials after having received two or more previous treatment regimens. We found that 31 percent of patients who used our database to search for clinical trials in 2018 were looking for their third (or more) treatment option. This number is up from 25 percent from 2016, suggesting that more patients are considering clinical trial enrollment later in their treatment journey.

Learn About Clinical Trials

Clinical Trials-related News

View More News →

Our Published Research

As part of PanCAN's strategic approach to increase survival, our Scientific and Medical Affairs team conducts independent and collaborative research to drive progress and improve patients' lives.

"We do not stand on the sidelines. We are working with researchers to make real progress for patients."

— Lynn Matrisian, PhD, MBA, Chief Science Officer

Explore Our Research

Evaluation of Research Grants Program

Every two years, we thoroughly evaluate our research grants program to assess its effectiveness in building a comprehensive research community and moving the science toward a cure. Read more about the impact of the PanCAN research grants program.

Learn More

Research Grants Database

PanCAN launched its Research Grants Program in 2003. Search our database to find grant recipients and projects categorized by year, type or topic.

Browse our Database

Wage Hope With Us

Join us to make a difference for pancreatic cancer patients.

shop purple logo

Gear, apparel, accessories and more to show off your purple pride.

Shop Now 

©2020 Pancreatic Cancer Action Network. All rights reserved. Terms of Use | Privacy Policy

Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision Promise℠ and Demand Better For Patients. For Survival.℠ are the trademarks of the Pancreatic Cancer Action Network, Inc.

The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.